Cellectar Biosciences Inc
NASDAQ:CLRB
Cellectar Biosciences Inc
NASDAQ:CLRB
Price:
2.7
USD
-6.9%
Market Cap:
$11.4m
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
US |
|
SunMoon Food Company Ltd
SGX:AAJ
|
SG |
|
Chevalier International Holdings Ltd
HKEX:25
|
HK |
|
L1 Group Ltd
F:PIJ0
|
AU |
|
K
|
Keynote Financial Services Ltd
NSE:KEYFINSERV
|
IN |
|
GlycoMimetics Inc
NASDAQ:GLYC
|
US |
|
A
|
Aidemy Inc
TSE:5577
|
JP |
|
Forrester Research Inc
NASDAQ:FORR
|
US |
|
Titan Medical Inc
TSX:TMD
|
CA |
|
Wall Street Finance Ltd
BSE:511147
|
IN |
|
Fortitude Gold Corp
OTC:FTCO
|
US |
|
Avnet Inc
NASDAQ:AVT
|
US |
|
Q
|
Q & M Dental Group (Singapore) Ltd
XBER:QMBN
|
SG |
Multiples-Based Value
The Multiples-Based Value of one
CLRB
stock under the Base Case scenario is
hidden
USD.
Compared to the current market price of 2.7 USD,
Cellectar Biosciences Inc
is
hidden
.
Multiples-Based Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
CLRB Multiples-Based Value
LOCKED
Multiples Across Competitors
CLRB Competitors Multiples
Cellectar Biosciences Inc Competitors
Cellectar Biosciences Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| US |
|
Cellectar Biosciences Inc
NASDAQ:CLRB
|
11.4m USD | 0 | -0.5 | 0.1 | 0.1 | |
| FR |
|
Pharnext SCA
OTC:PNEXF
|
6T USD | 33 690 872.8 | -160 127.7 | -194 446.1 | -192 227.3 | |
| US |
|
Abbvie Inc
NYSE:ABBV
|
370.2B USD | 6.2 | 90.1 | 14.9 | 20.7 | |
| US |
|
Exact Sciences Corp
NASDAQ:EXAS
|
356.2B USD | 109.7 | -1 712.3 | 15 906.4 | -1 796.1 | |
| US |
|
Amgen Inc
NASDAQ:AMGN
|
188B USD | 5.1 | 24.5 | 14.2 | 14.2 | |
| US |
|
Gilead Sciences Inc
NASDAQ:GILD
|
166.6B USD | 5.8 | 19.9 | 12.5 | 15.4 | |
| US |
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
110B USD | 9.4 | 28.4 | 21.3 | 22.3 | |
| US |
E
|
Epizyme Inc
F:EPE
|
94.1B EUR | 2 091 | -533.6 | -581 | -565.5 | |
| US |
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
78B USD | 5.5 | 17.6 | 13 | 14.9 | |
| AU |
|
CSL Ltd
ASX:CSL
|
69B AUD | 3.1 | 34.4 | 11.4 | 14.3 | |
| US |
S
|
Seagen Inc
F:SGT
|
39.3B EUR | 20.1 | -61.8 | -66.6 | -60.1 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
